1-(3-氯苯基)-2-羟基-2-(3-苯基甲氧基苯基)乙酮 | 721428-21-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: 1-(3-氯苯基)-2-羟基-2-(3-苯基甲氧基苯基)乙酮
• 英文名称: 2-(3-benzyloxyphenyl)-1-(3-chlorophenyl)-2-hydroxyethan-1-one
• 英文别名: 2-[3-(Benzyloxy)phenyl]-1-(3-chlorophenyl)-2-hydroxyethan-1-one；1-(3-chlorophenyl)-2-hydroxy-2-(3-phenylmethoxyphenyl)ethanone
• CAS: 721428-21-3
• 化学式: C₂₁H₁₇ClO₃
• 分子量: 352.817
• InChiKey: SBLSPCQYJHTCHI-UHFFFAOYSA-N

物化性质

• 沸点：
  534.2±50.0 °C(Predicted)
• 密度：
  1.275±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3-氯苯基)-2-羟基-2-(3-苯基甲氧基苯基)乙酮 在 吡啶 、 ammonium acetate 、 copper(II) sulfate 、 溶剂黄146 作用下， 以 水 为溶剂， 生成 5-(3-benzylohyphenyl)-4-(3-chlorophenyl)-2-(4-piperidyl)imidazole dihydrochloride
  参考文献：
  名称：

  Synthesis and antibacterial activity of novel and potent DNA gyrase inhibitors with azole ring

  摘要：

  The 4-piperidyl moiety and the pyrazole ring in 1-(3-chlorophenyl)-5-(4-phenoxyphenyl)-3-(4-piperidyl)pyrazole 2, which has previously shown improved DNA gyrase inhibition and target-related antibacterial activity, were transformed to other groups and the in vitro antibacterial activity of the synthesized compounds was evaluated. The selected pyrazole, oxazole and imidazole derivatives showed moderate inhibition against DNA gyrase and topoisomerase IV with similar IC50 values (IC50 = 9.4-25 mug/mL). In addition, many of the pyrazole, oxazole and imidazole derivatives synthesized in this study exhibited potent antibacterial activity against quinolone-resistant clinical isolates and coumarin-resistant laboratory isolates of Gram-positive bacteria with minimal inhibitory concentration values equivalent to those against susceptible strains. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.08.010
• 作为产物：
  描述：

  2-(3-chlorophenyl)-2-((trimethylsilyl)oxy)acetonitrile 、 间苯氧基苯甲醛 在 lithium hexamethyldisilazane 、 硫酸 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 1-(3-氯苯基)-2-羟基-2-(3-苯基甲氧基苯基)乙酮
  参考文献：
  名称：

  Synthesis and antibacterial activity of novel and potent DNA gyrase inhibitors with azole ring

  摘要：

  The 4-piperidyl moiety and the pyrazole ring in 1-(3-chlorophenyl)-5-(4-phenoxyphenyl)-3-(4-piperidyl)pyrazole 2, which has previously shown improved DNA gyrase inhibition and target-related antibacterial activity, were transformed to other groups and the in vitro antibacterial activity of the synthesized compounds was evaluated. The selected pyrazole, oxazole and imidazole derivatives showed moderate inhibition against DNA gyrase and topoisomerase IV with similar IC50 values (IC50 = 9.4-25 mug/mL). In addition, many of the pyrazole, oxazole and imidazole derivatives synthesized in this study exhibited potent antibacterial activity against quinolone-resistant clinical isolates and coumarin-resistant laboratory isolates of Gram-positive bacteria with minimal inhibitory concentration values equivalent to those against susceptible strains. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.08.010

文献信息

• Synthesis and antibacterial activity of novel and potent DNA gyrase inhibitors with azole ring
  作者：Akihiko Tanitame、Yoshihiro Oyamada、Keiko Ofuji、Mika Fujimoto、Kenji Suzuki、Tomohiko Ueda、Hideo Terauchi、Motoji Kawasaki、Kazuo Nagai、Masaaki Wachi、Jun-ichi Yamagishi

  DOI：10.1016/j.bmc.2004.08.010

  日期：2004.11

  The 4-piperidyl moiety and the pyrazole ring in 1-(3-chlorophenyl)-5-(4-phenoxyphenyl)-3-(4-piperidyl)pyrazole 2, which has previously shown improved DNA gyrase inhibition and target-related antibacterial activity, were transformed to other groups and the in vitro antibacterial activity of the synthesized compounds was evaluated. The selected pyrazole, oxazole and imidazole derivatives showed moderate inhibition against DNA gyrase and topoisomerase IV with similar IC50 values (IC50 = 9.4-25 mug/mL). In addition, many of the pyrazole, oxazole and imidazole derivatives synthesized in this study exhibited potent antibacterial activity against quinolone-resistant clinical isolates and coumarin-resistant laboratory isolates of Gram-positive bacteria with minimal inhibitory concentration values equivalent to those against susceptible strains. (C) 2004 Elsevier Ltd. All rights reserved.